Prophylactic administration of recombinant human thrombopoietin attenuates XELOX or SOX regimen-induced thrombocytopaenia

Arch Med Sci. 2021 Aug 9;17(5):1440-1446. doi: 10.5114/aoms/141134. eCollection 2021.NO ABSTRACTPMID:34522277 | PMC:PMC8425230 | DOI:10.5114/aoms/141134
Source: Archives of Medical Science - Category: Biomedical Science Authors: Source Type: research